NO314730B1 - Nye dipeptidforbindelser eller farmasöytisk akseptable salter derav og anvendelse derav til fremstilling av preparater, samt anti-AIDS-middelog fremgangsmåte for fremstilling av slike forbindelser - Google Patents
Nye dipeptidforbindelser eller farmasöytisk akseptable salter derav og anvendelse derav til fremstilling av preparater, samt anti-AIDS-middelog fremgangsmåte for fremstilling av slike forbindelser Download PDFInfo
- Publication number
- NO314730B1 NO314730B1 NO19962748A NO962748A NO314730B1 NO 314730 B1 NO314730 B1 NO 314730B1 NO 19962748 A NO19962748 A NO 19962748A NO 962748 A NO962748 A NO 962748A NO 314730 B1 NO314730 B1 NO 314730B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- compound
- general formula
- hydroxy
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 222
- 108010016626 Dipeptides Proteins 0.000 title claims abstract description 66
- 150000003839 salts Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 28
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 title description 4
- -1 chloromethylene Chemical group 0.000 claims abstract description 39
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 15
- 208000030507 AIDS Diseases 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 9
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 5
- 125000003277 amino group Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000006181 N-acylation Effects 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000005727 virus proliferation Effects 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 238000005917 acylation reaction Methods 0.000 claims 1
- 108010010369 HIV Protease Proteins 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 125000001931 aliphatic group Chemical group 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract description 2
- 229930195733 hydrocarbon Natural products 0.000 abstract description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 85
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 73
- 239000000047 product Substances 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 230000014759 maintenance of location Effects 0.000 description 44
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 42
- 238000000746 purification Methods 0.000 description 37
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 35
- 239000000725 suspension Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 239000004030 hiv protease inhibitor Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 20
- 235000019341 magnesium sulphate Nutrition 0.000 description 20
- 229940122440 HIV protease inhibitor Drugs 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- RIERSGULWXEJKL-UHFFFAOYSA-N 3-hydroxy-2-methylbenzoic acid Chemical compound CC1=C(O)C=CC=C1C(O)=O RIERSGULWXEJKL-UHFFFAOYSA-N 0.000 description 11
- 238000009833 condensation Methods 0.000 description 11
- 230000005494 condensation Effects 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000036436 anti-hiv Effects 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- RCGJBBOBRZDMTL-UHFFFAOYSA-N 2-ethyl-3-hydroxybenzoic acid Chemical compound CCC1=C(O)C=CC=C1C(O)=O RCGJBBOBRZDMTL-UHFFFAOYSA-N 0.000 description 5
- NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108010075606 kynostatin 272 Proteins 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 150000001718 carbodiimides Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- LDSJMFGYNFIFRK-IUCAKERBSA-N (2s,3s)-3-azaniumyl-2-hydroxy-4-phenylbutanoate Chemical compound OC(=O)[C@@H](O)[C@@H](N)CC1=CC=CC=C1 LDSJMFGYNFIFRK-IUCAKERBSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- IHCCAYCGZOLTEU-UHFFFAOYSA-N 3-furoic acid Chemical compound OC(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 2
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229960000523 zalcitabine Drugs 0.000 description 2
- CJAAPVQEZPAQNI-UHFFFAOYSA-N (2-methylphenyl)methanamine Chemical compound CC1=CC=CC=C1CN CJAAPVQEZPAQNI-UHFFFAOYSA-N 0.000 description 1
- BHTRKISIDQZUQX-RYUDHWBXSA-N (2s,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@H](O)C(O)=O)CC1=CC=CC=C1 BHTRKISIDQZUQX-RYUDHWBXSA-N 0.000 description 1
- PJAKYCZLEXWQFQ-CSGPRLQLSA-N (2s,4s)-n-tert-butyl-4-chloro-3-[(2s,3s)-3-[(2-ethyl-3-hydroxybenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]pyrrolidine-2-carboxamide Chemical compound CCC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)C1[C@H](NC[C@H]1Cl)C(=O)NC(C)(C)C)CC1=CC=CC=C1 PJAKYCZLEXWQFQ-CSGPRLQLSA-N 0.000 description 1
- NRQHBNNTBIDSRK-YRNVUSSQSA-N (4e)-4-[(4-methoxyphenyl)methylidene]-2-methyl-1,3-oxazol-5-one Chemical compound C1=CC(OC)=CC=C1\C=C\1C(=O)OC(C)=N/1 NRQHBNNTBIDSRK-YRNVUSSQSA-N 0.000 description 1
- FJWNZTPXVSWUKF-LURJTMIESA-N (4r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CSC[C@H]1C(O)=O FJWNZTPXVSWUKF-LURJTMIESA-N 0.000 description 1
- CUFQBQOBLVLKRF-RZDMPUFOSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(O)C=CC=1)C)CC1=CC=CC=C1 CUFQBQOBLVLKRF-RZDMPUFOSA-N 0.000 description 1
- MMCLAFJWSPFWJN-KLJDGLGGSA-N (4r)-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@H]1N(C(=O)[C@@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)C=2C(=C(O)C=CC=2)C)CSC1 MMCLAFJWSPFWJN-KLJDGLGGSA-N 0.000 description 1
- ADHNDUSYFBBCMD-NSVAZKTRSA-N (4r)-3-[(2s,3s)-3-[(2-ethyl-3-hydroxybenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CCC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NCC=1C(=CC=CC=1)C)CC1=CC=CC=C1 ADHNDUSYFBBCMD-NSVAZKTRSA-N 0.000 description 1
- GTNHNXIXRTXVNB-YTCPBCGMSA-N (4r)-3-[(2s,3s)-3-[(3-amino-2-ethylbenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CCC1=C(N)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](C(C)(C)SC1)C(=O)NCC=1C(=CC=CC=1)C)CC1=CC=CC=C1 GTNHNXIXRTXVNB-YTCPBCGMSA-N 0.000 description 1
- YLVSKLSTQMQGJB-KCHLEUMXSA-N (4r)-3-[(2s,3s)-3-[(3-amino-2-ethylbenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CCC1=C(N)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NCC=1C(=CC=CC=1)C)CC1=CC=CC=C1 YLVSKLSTQMQGJB-KCHLEUMXSA-N 0.000 description 1
- OHWVRHZAWOCYCD-KMDXXIMOSA-N (4r)-3-[(2s,3s)-3-[(3-amino-2-ethylbenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-n-tert-butyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide Chemical compound CCC1=C(N)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](C(C)(C)SC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 OHWVRHZAWOCYCD-KMDXXIMOSA-N 0.000 description 1
- XVATZIVMCDYNBG-HZFUHODCSA-N (4r)-3-[(2s,3s)-3-[(3-amino-2-methylbenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@@H]1C(C)(C)SCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=C(N)C=CC=1)C)CC1=CC=CC=C1 XVATZIVMCDYNBG-HZFUHODCSA-N 0.000 description 1
- DWMBYDGDFLQRJS-QKDODKLFSA-N (4r)-3-[(2s,3s)-3-[(3-amino-2-methylbenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@H]1N(C(=O)[C@@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)C=2C(=C(N)C=CC=2)C)CSC1 DWMBYDGDFLQRJS-QKDODKLFSA-N 0.000 description 1
- FPZFFWRUKOCEBA-RJGXRXQPSA-N (4r)-3-[(2s,3s)-3-[(3-amino-2-methylbenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-n-tert-butyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide Chemical compound CC1=C(N)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](C(C)(C)SC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 FPZFFWRUKOCEBA-RJGXRXQPSA-N 0.000 description 1
- AALDFNHARUKGFO-NSVAZKTRSA-N (4r)-n-[(2,6-dimethylphenyl)methyl]-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC(C)=C1CNC(=O)[C@H]1N(C(=O)[C@@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)C=2C(=C(O)C=CC=2)C)CSC1 AALDFNHARUKGFO-NSVAZKTRSA-N 0.000 description 1
- YNWSJDQCKUVRGB-GNKBHMEESA-N (4r)-n-[(2-chlorophenyl)methyl]-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NCC=1C(=CC=CC=1)Cl)CC1=CC=CC=C1 YNWSJDQCKUVRGB-GNKBHMEESA-N 0.000 description 1
- ZGQZLXSZBYZZLN-DOEKTCAHSA-N (4r)-n-[(2-chlorophenyl)methyl]-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](C(C)(C)SC1)C(=O)NCC=1C(=CC=CC=1)Cl)CC1=CC=CC=C1 ZGQZLXSZBYZZLN-DOEKTCAHSA-N 0.000 description 1
- QDHWCGWPVIQSMA-NSHDSACASA-N (4r)-n-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=CC=CC=C1CNC(=O)[C@H]1NCSC1 QDHWCGWPVIQSMA-NSHDSACASA-N 0.000 description 1
- ZQDFGFLALOATID-BVSLBCMMSA-N (4r)-n-tert-butyl-3-[(2s,3s)-2-hydroxy-3-[(2-methyl-3,5-dinitrobenzoyl)amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide Chemical compound C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C)=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 ZQDFGFLALOATID-BVSLBCMMSA-N 0.000 description 1
- DBZLZNFYSDUNIS-ONTIZHBOSA-N (4r)-n-tert-butyl-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 DBZLZNFYSDUNIS-ONTIZHBOSA-N 0.000 description 1
- CGFVYUGIPISJQG-ACIOBRDBSA-N (4r)-n-tert-butyl-3-[(2s,3s)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](C(C)(C)SC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 CGFVYUGIPISJQG-ACIOBRDBSA-N 0.000 description 1
- ZHYBRFRKLLDIDG-FUDKSRODSA-N (4r)-n-tert-butyl-3-[(2s,3s)-3-[(2-ethyl-3-hydroxybenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide Chemical compound CCC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 ZHYBRFRKLLDIDG-FUDKSRODSA-N 0.000 description 1
- POTILZIEQCOPAG-OEMFJLHTSA-N (4r)-n-tert-butyl-3-[(2s,3s)-3-[(2-ethyl-3-hydroxybenzoyl)amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide Chemical compound CCC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)C(=O)N1[C@@H](C(C)(C)SC1)C(=O)NC(C)(C)C)CC1=CC=CC=C1 POTILZIEQCOPAG-OEMFJLHTSA-N 0.000 description 1
- IFNULYQZWRMFCP-RQJHMYQMSA-N (4s,5r)-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-oxazolidine-4-carboxylic acid Chemical compound C[C@H]1OCN(C(=O)OC(C)(C)C)[C@@H]1C(O)=O IFNULYQZWRMFCP-RQJHMYQMSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- XFZIPCXDWCWTCH-UHFFFAOYSA-N 1,3-oxazolidin-3-ium-4-carboxylate Chemical compound OC(=O)C1COCN1 XFZIPCXDWCWTCH-UHFFFAOYSA-N 0.000 description 1
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
- BYGHHEDJDSLEKK-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C(O)=O BYGHHEDJDSLEKK-UHFFFAOYSA-N 0.000 description 1
- DGJZQGIPRSNYGE-ACRUOGEOSA-N 2-[[(2s,3s)-4-[(4r)-4-(tert-butylcarbamoyl)-1,3-thiazolidin-3-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]carbamoyl]benzoic acid Chemical compound CC(C)(C)NC(=O)[C@@H]1CSCN1C(=O)[C@@H](O)[C@@H](NC(=O)C=1C(=CC=CC=1)C(O)=O)CC1=CC=CC=C1 DGJZQGIPRSNYGE-ACRUOGEOSA-N 0.000 description 1
- DNUYOWCKBJFOGS-UHFFFAOYSA-N 2-[[10-(2,2-dicarboxyethyl)anthracen-9-yl]methyl]propanedioic acid Chemical compound C1=CC=C2C(CC(C(=O)O)C(O)=O)=C(C=CC=C3)C3=C(CC(C(O)=O)C(O)=O)C2=C1 DNUYOWCKBJFOGS-UHFFFAOYSA-N 0.000 description 1
- XMQYBJNICRKTBW-UHFFFAOYSA-N 2-[[2-[[1-[2-[[4-amino-2-[[5-amino-2-[(2-amino-3-hydroxypropanoyl)amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)C(C(O)=O)NC(=O)C(C(C)CC)NC(=O)C1CCCN1C(=O)C(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(N)CO)CC1=CC=C(O)C=C1 XMQYBJNICRKTBW-UHFFFAOYSA-N 0.000 description 1
- CDVNZMKTJIBBBV-UHFFFAOYSA-N 2-methyl-3,5-dinitrobenzoic acid Chemical compound CC1=C(C(O)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CDVNZMKTJIBBBV-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- SAPAUOFSCLCQJB-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C(O)=O)=C1 SAPAUOFSCLCQJB-UHFFFAOYSA-N 0.000 description 1
- BYHMLZGICSEKIY-UHFFFAOYSA-N 3-amino-2-methylbenzoic acid Chemical compound CC1=C(N)C=CC=C1C(O)=O BYHMLZGICSEKIY-UHFFFAOYSA-N 0.000 description 1
- OSMPVDKPQINFEZ-UHFFFAOYSA-N 3-hydroxy-2-propylbenzoic acid Chemical compound CCCC1=C(O)C=CC=C1C(O)=O OSMPVDKPQINFEZ-UHFFFAOYSA-N 0.000 description 1
- ZJDBQMWMDZEONW-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C(O)=O)C=C1 ZJDBQMWMDZEONW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- UYZNMRJCNSDDFV-UHFFFAOYSA-N 4-chloropyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CC(Cl)CN1 UYZNMRJCNSDDFV-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- REIDAMBAPLIATC-UHFFFAOYSA-M 4-methoxycarbonylbenzoate Chemical compound COC(=O)C1=CC=C(C([O-])=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical class Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IJFXRHURBJZNAO-UHFFFAOYSA-N meta--hydroxybenzoic acid Natural products OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18815195 | 1995-06-30 | ||
| JP14067896 | 1996-05-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962748D0 NO962748D0 (no) | 1996-06-28 |
| NO962748L NO962748L (no) | 1997-01-02 |
| NO314730B1 true NO314730B1 (no) | 2003-05-12 |
Family
ID=26473119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19962748A NO314730B1 (no) | 1995-06-30 | 1996-06-28 | Nye dipeptidforbindelser eller farmasöytisk akseptable salter derav og anvendelse derav til fremstilling av preparater, samt anti-AIDS-middelog fremgangsmåte for fremstilling av slike forbindelser |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5932550A (de) |
| EP (1) | EP0751145B1 (de) |
| AT (1) | ATE266039T1 (de) |
| AU (1) | AU705193B2 (de) |
| CA (1) | CA2179935C (de) |
| DE (1) | DE69632365T2 (de) |
| DK (1) | DK0751145T3 (de) |
| ES (1) | ES2220963T3 (de) |
| NO (1) | NO314730B1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313094B1 (en) | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| US6803466B1 (en) * | 1997-12-08 | 2004-10-12 | The Scripps Research Institute | HIV/FIV protease inhibitors having a small P3 residue |
| AU1904599A (en) * | 1997-12-08 | 1999-06-28 | Scripps Research Institute, The | Hiv/fiv protease inhibitors having a small p3 residue |
| WO2001047948A1 (fr) * | 1999-12-28 | 2001-07-05 | Japan Energy Corporation | Nouveau composé dipeptidique et ses applications en médecine |
| US6589962B1 (en) | 1999-07-20 | 2003-07-08 | Merck & Co., Inc. | Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof |
| CA2378480A1 (en) * | 1999-08-09 | 2001-02-15 | Tripep Ab | Pharmaceutical compositions containing tripeptides |
| US6287688B1 (en) * | 2000-03-03 | 2001-09-11 | E. I. Du Pont De Nemours And Company | Partially oriented poly(trimethylene terephthalate) yarn |
| HN2002000136A (es) * | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| US7094909B2 (en) * | 2001-06-11 | 2006-08-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| US7169932B2 (en) | 2001-06-11 | 2007-01-30 | Pfizer Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis |
| US6593455B2 (en) * | 2001-08-24 | 2003-07-15 | Tripep Ab | Tripeptide amides that block viral infectivity and methods of use thereof |
| EP1436317A1 (de) * | 2001-09-19 | 2004-07-14 | Tripep Ab | Moleküle, die die virale infektivität hemmen, und verfahren zu deren anwendung |
| WO2004073703A1 (en) * | 2003-02-21 | 2004-09-02 | Tripep Ab | Glycinamide derivative for inhibiting hiv replication |
| US20050096319A1 (en) * | 2003-02-21 | 2005-05-05 | Balzarini Jan M.R. | Identification of compounds that inhibit replication of human immunodeficiency virus |
| US6955002B2 (en) * | 2003-03-18 | 2005-10-18 | Sandel Medical Industries Llc | Medication marking system |
| WO2005026114A1 (en) * | 2003-09-17 | 2005-03-24 | Pfizer Inc. | Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses |
| CA2549289A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Inc. | Methods for the preparation of stereoisomerically enriched amines |
| KR20060097047A (ko) * | 2003-12-04 | 2006-09-13 | 화이자 인코포레이티드 | 프로테아제 억제제로서 유용한 화합물의 제조 방법 |
| CA2549290A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Inc. | Methods of preparing compounds useful as protease inhibitors |
| CA2835216A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| EP2714648B1 (de) * | 2011-05-31 | 2017-08-16 | Theravance Biopharma R&D IP, LLC | Neprilysin-inhibitoren |
| WO2012166390A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003842A1 (en) * | 1987-10-21 | 1989-05-05 | The Upjohn Company | Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety |
| US4963655A (en) * | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
| US5086165A (en) * | 1989-03-08 | 1992-02-04 | Washington University | Inhibitors of retroviral protease with a ketomethylene isosteric replaced amide bond |
| US5342922A (en) * | 1989-03-08 | 1994-08-30 | Washington University | Inhibitors of retroviral protease |
| DE3913272A1 (de) * | 1989-04-22 | 1990-10-25 | Hoechst Ag | Dipeptid-derivate mit enzym-inhibitorischer wirkung |
| US5212157A (en) * | 1989-06-06 | 1993-05-18 | Bio-Mega, Inc. | Enzyme inhibitors |
| US5126326A (en) * | 1989-06-06 | 1992-06-30 | Bio-Mega, Inc. | Enzyme inhibiting peptide derivatives |
| DE4001236A1 (de) * | 1990-01-18 | 1991-07-25 | Bayer Ag | Neue peptide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, insbesondere als arzneimittel gegen retroviren |
| EP0438311A3 (en) * | 1990-01-19 | 1992-07-01 | Merck & Co. Inc. | Di- and tripeptide renin inhibitors |
| EP0546115A1 (de) * | 1990-08-24 | 1993-06-16 | The Upjohn Company | Peptide mit aminopolyolen als übergangszustandsimitatoren |
| US5192668A (en) * | 1990-10-11 | 1993-03-09 | Merck & Co., Inc. | Synthesis of protease inhibitor |
| US5188950A (en) * | 1990-10-11 | 1993-02-23 | Merck & Co., Inc. | Method of preparing HIV protease inhibitors |
| US5187074A (en) * | 1990-10-11 | 1993-02-16 | Merck & Co., Inc. | Method of hydroxylation with ATCC 55086 |
| US5475013A (en) * | 1990-11-19 | 1995-12-12 | Monsanto Company | Retroviral protease inhibitors |
| AU9122391A (en) * | 1990-11-30 | 1992-06-25 | Smithkline Beecham Corporation | Hiv protease inhibitors |
| CA2056911C (en) * | 1990-12-11 | 1998-09-22 | Yuuichi Nagano | Hiv protease inhibitors |
| IL100899A (en) * | 1991-02-08 | 1997-06-10 | Sankyo Co | Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| IE922316A1 (en) * | 1991-07-17 | 1993-01-27 | Smithkline Beecham Corp | Retroviral protease inhibitors |
| WO1993008184A1 (en) * | 1991-10-23 | 1993-04-29 | Merck & Co., Inc. | Hiv protease inhibitors |
| US5644028A (en) * | 1992-05-13 | 1997-07-01 | Japan Energy Corporation | Process for producing peptide derivatives and salts therefor |
| ZA935697B (en) * | 1992-08-07 | 1994-03-10 | Sankyo Co | Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use |
| US5491166A (en) * | 1992-12-22 | 1996-02-13 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of AIDS |
| DE69329544T2 (de) * | 1992-12-22 | 2001-05-31 | Lilly Co Eli | HIV Protease hemmende Verbindungen |
| MX9308016A (es) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. |
| US5554653A (en) * | 1992-12-22 | 1996-09-10 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of AIDS |
| US5434265A (en) * | 1992-12-22 | 1995-07-18 | Eli Lilly And Company | Inhibitors of HIV protease |
| WO1994018192A1 (en) * | 1993-02-12 | 1994-08-18 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
| AU6828894A (en) * | 1993-05-14 | 1994-12-12 | Merck & Co., Inc. | Hiv protease inhibitors |
| US5587514A (en) * | 1993-11-08 | 1996-12-24 | Emory University | Diastereoselective synthesis of hydroxyethylene dipeptide isosteres |
| US5476874A (en) * | 1994-06-22 | 1995-12-19 | Merck & Co., Inc. | New HIV protease inhibitors |
| US5492910A (en) * | 1994-11-17 | 1996-02-20 | Bristol-Myers Squibb Co. | Retrocarbamate protease inhibitors |
| WO1996028423A1 (fr) * | 1995-03-15 | 1996-09-19 | Sankyo Company, Limited | Composes dipeptidiques de structure ahpba |
-
1996
- 1996-06-26 CA CA2179935A patent/CA2179935C/en not_active Expired - Fee Related
- 1996-06-26 US US08/669,757 patent/US5932550A/en not_active Expired - Lifetime
- 1996-06-28 ES ES96304764T patent/ES2220963T3/es not_active Expired - Lifetime
- 1996-06-28 EP EP96304764A patent/EP0751145B1/de not_active Expired - Lifetime
- 1996-06-28 DE DE69632365T patent/DE69632365T2/de not_active Expired - Lifetime
- 1996-06-28 DK DK96304764T patent/DK0751145T3/da active
- 1996-06-28 AU AU56285/96A patent/AU705193B2/en not_active Ceased
- 1996-06-28 NO NO19962748A patent/NO314730B1/no not_active IP Right Cessation
- 1996-06-28 AT AT96304764T patent/ATE266039T1/de active
-
1998
- 1998-08-21 US US09/137,608 patent/US5962640A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0751145A3 (de) | 1997-10-08 |
| US5962640A (en) | 1999-10-05 |
| ES2220963T3 (es) | 2004-12-16 |
| ATE266039T1 (de) | 2004-05-15 |
| NO962748L (no) | 1997-01-02 |
| AU5628596A (en) | 1997-02-06 |
| DE69632365T2 (de) | 2005-05-04 |
| DE69632365D1 (de) | 2004-06-09 |
| EP0751145A2 (de) | 1997-01-02 |
| CA2179935C (en) | 2010-09-07 |
| NO962748D0 (no) | 1996-06-28 |
| AU705193B2 (en) | 1999-05-20 |
| CA2179935A1 (en) | 1996-12-31 |
| US5932550A (en) | 1999-08-03 |
| DK0751145T3 (da) | 2004-08-30 |
| EP0751145B1 (de) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314730B1 (no) | Nye dipeptidforbindelser eller farmasöytisk akseptable salter derav og anvendelse derav til fremstilling av preparater, samt anti-AIDS-middelog fremgangsmåte for fremstilling av slike forbindelser | |
| KR102582886B1 (ko) | 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법 | |
| ES2256421T3 (es) | Sulfonil derivados de aminoacidos y su utilizacion como inhibidores de deipeptidil-peptidasa iv (dpp iv). | |
| ES2336009T3 (es) | Inhibidores de la ns-3 serina proteasa del vhc. | |
| JP2002363157A (ja) | 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物 | |
| US20060258868A1 (en) | Hepatitis c inhibitor peptide analogs | |
| AU2009303483A1 (en) | Therapeutic antiviral peptides | |
| SK51099A3 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease | |
| HU227882B1 (hu) | Prolinszármazékok és gyógyszerként való alkalmazásuk | |
| CA2291778A1 (en) | Heterocyclic amide compounds as cell adhesion inhibitors | |
| WO1999064395A1 (en) | Heterocyclic amide compounds as cell adhesion inhibitors | |
| CA3210873A1 (en) | Compounds, compositions, and methods of using the same | |
| WO1993005014A1 (en) | Aromatic sulfonamide derivatives, their use as enzyme inhibitors and pharmaceutical compositions containing them | |
| Shin et al. | Novel synthesis of the main central 2, 3, 6-trisubstituted pyridine skeleton [Fragment ABC] of a macrobicyclic antibiotic, cyclothiazomycin | |
| US6222043B1 (en) | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof | |
| WO2006133338A1 (en) | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | |
| JPWO2006070780A1 (ja) | Ｐａｒ−２アゴニスト | |
| US6673772B2 (en) | Dipeptide compounds and their use as antiviral agents | |
| US6291432B1 (en) | Tripeptide compounds and anti-AIDS medicine | |
| JP3408379B2 (ja) | 新規なジペプチド化合物又はその薬理的に許容される塩及びその医薬用途 | |
| AU779356B2 (en) | Novel dipeptide compound and medicinal use thereof | |
| JPH10101654A (ja) | 新規なジペプチド化合物又はその薬理的に許容される塩及びその医薬用途 | |
| JPH08259532A (ja) | ペプチド様化合物又はその薬理的に許容される塩 | |
| EP1864994A1 (de) | Par-2-agonist | |
| IE870861L (en) | Azepine and thiazepine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |